Catalyst
Slingshot members are tracking this event:
Prothena (PRTA) aiming to enroll Phase 3 VITAL Amyloidosis study—using NEOD001 for patients with AL Amyloidosis in cardiac dysfunction—in Q2 of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PRTA | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 25, 2017
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02312206?term=NEOD001&rank=4
Related Projects
- What can we expect from the upcoming data releases of Prothena’s Phase 3 VITAL and Phase 2b PRONTO Amyloidosis Studies? PRTA, TKPYY Executed On: Sep 13, 2017 at 10:30 AM EDT
Related Keywords
Phase 3 Study, Vital, Amyloidosis, Neod001, Cardiac Dysfunction
